Vertex Pharma stock at EUR 464.48 ahead of the Xetra open: biotech group

Published on 10/22/2026 at 07:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharmaceuticals develops and commercializes medicines for serious diseases. At Lang & Schwarz, the stock trades pre-market at EUR 464.48 on October 22, 2026.

Business model and market

Vertex Pharmaceuticals develops and commercializes medicines for serious diseases.
The company’s primary listing is on Nasdaq.
Vertex Pharma stock trades pre-market at EUR 464.48 at 7:44 a.m. CEST at Lang & Schwarz on October 22, 2026.

Wissenschaftler pipettiert Proben in modernem Biotech-Labor mit Automatisierungsgeräten — Vertex Pharma US92532F1003 zeigt einen Forscher im modernen Labor mit Pipette an sterilem Edelstahltisch, Illustration mit AI erstellt.

Vertex Pharmaceuticals develops and commercializes medicines for serious diseases, according to MarketBeat. At 7:44 a.m. CEST on October 22, 2026, Vertex Pharma stock traded pre-market at EUR 464.48 at Lang & Schwarz.

First prices of the day

The quoted stock price was available before the Xetra open. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Vertex Pharma stock.

The group and its market

Vertex Pharmaceuticals is listed on the Nasdaq under the ticker VRTX, while its business focuses on medicines for serious diseases, including treatments for cystic fibrosis, according to MarketBeat.

Market context: Market report S&P 500.

More news and analysis on Vertex Pharma stock